LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

LLY

1,015.45

-0.45%↓

JNJ

245.44

+0.71%↑

ABBV

224.71

-0.94%↓

NVS

163.31

-1.57%↓

MRK

121.02

+0.26%↑

Search

Cytek Biosciences Inc

Avatud

SektorTervishoid

4.2 -0.24

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.12

Max

4.25

Põhinäitajad

By Trading Economics

Sissetulek

105K

-5.5M

Müük

6.7M

52M

Aktsiakasum

-0

Kasumimarginaal

-10.476

Töötajad

692

EBITDA

6.4M

-4.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+45.52% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

26. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

41M

542M

Eelmine avamishind

4.44

Eelmine sulgemishind

4.2

Uudiste sentiment

By Acuity

17%

83%

30 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. veebr 2026, 22:31 UTC

Tulu

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18. veebr 2026, 22:18 UTC

Tulu

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18. veebr 2026, 22:11 UTC

Tulu

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18. veebr 2026, 21:52 UTC

Tulu

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18. veebr 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18. veebr 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. veebr 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18. veebr 2026, 23:34 UTC

Market Talk
Tulu

Brambles' Cost Control Stands Out to Bull -- Market Talk

18. veebr 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18. veebr 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18. veebr 2026, 22:45 UTC

Tulu

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18. veebr 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18. veebr 2026, 22:37 UTC

Tulu

Nutrien 4Q EPS $1.18 >NTR.T

18. veebr 2026, 22:37 UTC

Tulu

Nutrien 4Q Sales $5.34B >NTR.T

18. veebr 2026, 22:35 UTC

Tulu

Pan American Silver 4Q EPS $1.07 >PAAS

18. veebr 2026, 22:35 UTC

Tulu

Pan American Silver 4Q Rev $1.18B >PAAS

18. veebr 2026, 22:30 UTC

Tulu

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18. veebr 2026, 22:29 UTC

Tulu

Kinross Gold 4Q EPS 75c >K.T

18. veebr 2026, 22:22 UTC

Tulu

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18. veebr 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18. veebr 2026, 22:16 UTC

Tulu

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18. veebr 2026, 22:05 UTC

Tulu

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18. veebr 2026, 22:03 UTC

Tulu

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q Sales $929M >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q EPS $1.68 >KALU

18. veebr 2026, 22:00 UTC

Tulu

Kinross Gold 4Q Adj EPS 67c >KGC

18. veebr 2026, 22:00 UTC

Tulu

Kinross Gold 4Q Sales $2.02B >KGC

18. veebr 2026, 21:56 UTC

Tulu

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18. veebr 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

45.52% tõus

12 kuu keskmine prognoos

Keskmine 6.17 USD  45.52%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

1

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

30 / 351 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat